New research volunteer registry: Volunteer information and biorepository

The Clinical and Translational Research Center now offers OHSU investigators access to a Research Volunteer Registry of subjects interested in participating in research projects. The registry also includes a biorepository with serum, plasma, urine, and saliva from healthy subjects. These biological samples are immediately available as control samples. You can access the volunteer names, contact information, and biological samples in this registry more quickly and less expensively than using traditional recruitment methods.

The CTRC has obtained IRB approval to share these names and samples with investigators. The volunteers have pre-consented to be contacted for future research studies with an umbrella IRB-approved consent form.  In most cases, investigators do not need to submit their own IRB protocols to access the biological samples. For volunteer names and contact information, the CTRC will work with investigators to obtain additional IRB approval in an expedited fashion if it is needed.

The registry currently has medical histories, medication lists, and contact information for more than 400 volunteers. Most subjects are healthy; some have chronic conditions. The biorepository currently houses biological samples from 140 healthy individuals who have no chronic medical conditions and take no medications.

The registry has already provided samples used as controls by the Knight BioLibrary and is providing samples to the OHSU-PNNL collaboration that supports the NIH Undiagnosed Diseases Network.

The CTRC is supported by the Oregon Clinical & Translational Research Institute. The Research Volunteer Registry expands OCTRI’s coordinated infrastructure of research tools that support research at OHSU. If you are interested in accessing volunteer names or biological samples, please contact the OCTRI Research Navigator at


OHSU innovators: Get support to commercialize your idea, Nov. 9

Technology Transfer and Business Development invites all OHSU innovators – faculty, students, fellows, employees – to a lunchtime gathering to learn about its expanded entrepreneur-in-residence program. Veterans Dick Rylander and Bob Masterson will be joined by two new entrepreneurs-in-residence Rob Arnold and Steve Runnels, who will share who will share details on how their expertise in starting health care and life science companies can help OHSU innovators commercialize their technologies. They will talk about how they support inventor teams and new companies that form when they license technology intellectual property from OHSU. Three new venture advisors, Eric Fogel, Mark Freiss, and Ron Nelson, will also discuss their roles in the expanded entrepreneur-in-residence program. As venture advisors, they might step in as an interim or full-time CEO in an OHSU company as part of the start-up process.

During the hour, in addition to hearing from experts, you can get advice for how to start or move forward with your idea, find a mentor, or schedule one-on-one conversations for a later date.

Entrepreneur-in-residence lunch and learn
Wednesday, Nov. 9
12 to 1 p.m.
Richard Jones Hall, room 4320

Feel free to bring your lunch. Light refreshments provided. To help us get an idea of attendance, please RSVP to

Questions? Read more about the entrepreneur-in-residence program or contact Daphne Emerson.


What’s new with NIH peer review? Nov. 3 and 10

You’re invited to hear a panel discussion with OHSU faculty who are currently serving on NIH study sections to learn about best practices for grant writing–and especially what they’re seeing in grants they’re reviewing with respect to the new requirements on rigor and reproducibility and more. Among other things, they will discuss guidance they’ve received from NIH as reviewers, as well as how study sections are responding. Bring your questions!

Two panel sessions will be held:csr-logo

Thursday, Nov. 3
11:30 a.m. – 1 p.m.

OHSU Auditorium


Thursday, Nov. 10
11:30 a.m. – 1 p.m.

Mackenzie Hall 1162

Questions? Contact us at

NINDS restructures funding support for postdocs

PrintThe National Institute of Neurological Disorders and Stroke will no longer participate in the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32). As of the Dec. 8, 2016 due date, F32 postdoctoral fellows research training support will be available through a separate announcement with several key differences from the parent F32. Most notably, applicants are only eligible prior to starting, or within the first 12 months of starting, their postdoctoral training. As such, no preliminary data are expected.

The NINDS F32 will support postdocs who are in their first three years of training in their sponsor’s lab. NINDS anticipates releasing a K01 announcement in time for the Feb. 12, 2017 initial receipt date that will allow applicants in their second through fourth year of training to apply.

Additionally, a webinar will be held on Dec. 13, 2016 from 3 – 4:00p.m. EST to walk potential applicants and mentors through the process of applying for the Diversity Advanced Postdoctoral Career Transition Award (K22). Hear from K22 awardees and reviewers about common mistakes and helpful tips.

Jan. 1: New F&A rates for non-clinical, industry-sponsored research

OHSU’s Facilities and Administrative rate for industry-sponsored research agreements will increase by 3%, effective January 1, 2017. The new rate will not apply to industry-sponsored clinical trials, federal awards such as SBIR/STTR awards, or ONPRC industry-sponsored agreements, but it will apply to all other industry-sponsored agreements entered into by Technology Transfer and Business Development on or after January 1, 2017. All currently funded projects will remain fixed at their awarded rate unless additional funding is added after January 1, 2017.

Beginning immediately, you should use the new rates to prepare proposal budgets for projects starting on or after January 1. Please contact your department administrator for questions with developing budgets using the new rates.

This is the first F&A rate increase for non-clinical industry-sponsored research agreements at OHSU since 2010. The change brings OHSU’s rate close to the average rate of the top 50 NIH grant recipients. The rate for externally sponsored research at OHSU will increase to 57% and other sponsored activity will increase to 35%. Rates for clinical projects will not change.

Technology Transfer and Business Development awards

Four OHSU researchers were honored at OHSU Technology Transfer and Business Development’s 11th award ceremony on Wednesday, Oct. 12. The event is held each year to honor members of the OHSU research community, recognize new companies based on OHSU technology, and celebrate TTBD’s numerous milestones and accomplishments.

Sudarshan Anand, Ph.D.

Sudarshan Anand, Ph.D.

Sudarshan Anand, Ph.D., assistant professor of cell and developmental biology, was recognized as New Inventor of the Year for his work with TTBD Understanding the role of microRNAs in cancer blood vessels and their response to DNA damaging agents is the major focus of Anand’s lab.

Matthew Hansen, M.D., M.C.R.

Matthew Hansen, M.D., M.C.R.

The Business Development Partnership Achievement Award was presented to Matthew Hansen, M.D., M.C.R.and David Sheridan, M.D., both assistant professors of pediatric emergency medicine in the OHSU School of Medicine and Doernbecher Children’s Hospital. The two have been instrumental in the success of OHSU’s partnership with Welch Allyn, Inc.

David Sheridan, M.D.

David Sheridan, M.D.

The Technology Transfer Achievement Award was presented to David Huang, M.D., Ph.D., Peterson Professor of Ophthalmology and professor of ophthalmology and biomedical engineering at the OHSU School of Medicine and the Casey Eye Institute. He was honored for his long-term work with TTBD and co-invention of optical coherence tomography.

David Huang, M.D., Ph.D.

David Huang, M.D., Ph.D.

The OHSU Clinical Trials Office Contracting Unit was recognized with the TTBD Appreciation Award for its ongoing collaboration with TTBD.

TTBD acknowledged new companies based on OHSU technology: CORI2, Inc., First Ascent Biomedical LLC, Project Lite, Inc., Qview Health, Inc., Regenavid, Inc., and SurgiVance, Inc.

The milestones and accomplishments celebrated by TTBD included the launch of the Improved Access to Technology (IMPACT) program and nearly $16 million in nonclinical industry-sponsored research awards.

Kristen Baptiste, J.D., Jenny Mair, J.D., Tara McKenzie, J.D., Jacqueline Brown, J.D., Colin Murphy, J.D., Emily Purdin

Kristen Baptiste, J.D., Jenny Mair, J.D., Tara McKenzie, J.D., Jacqueline Brown, J.D., Colin Murphy, J.D., Emily Purdin

Read the OHSU news release for more about the TTBD ceremony, the four faculty honorees, the new companies based on OHSU technology, and TTBD’s milestones and successes in 2016.

New federal policies issued on clinical trials

The NIH is the largest funder of clinical trials in the U.S., investing over $3 billion each year. Standards for scientific rigor and ethical oversight must be exceptionally high because the health and safety of human subjects are at stake. But challenges in the design, efficiency, and reporting of clinical trials are well documented–and may even threaten the progress of biomedicine.

Clinical trials journey and NIH stewardship reforms Taken from Sept. 16 NIH Extramural Nexus blog post

Clinical trials journey and NIH stewardship reforms. From Sept. 16 NIH Extramural Nexus.

In a recent JAMA article,  Kathy Hudson, Ph.D., deputy director for Science, Outreach and Policy at NIH, Michael Lauer, M.D., deputy director for extramural research, and NIH Director Francis Collins describe several new initiatives for improving clinical trials. Their aim is to catalyze more innovative and robust trial design and accelerated access to discoveries. Several new policies are being rolled out to this end.

1. The Department of Health and Human Services issued a new regulation and the National Institutes of Health rolled out a new policy to increase availability of information about clinical trials. The DHHS regulation, known as The Final Rule, implements existing FDA requirements to register and report clinical trials on The NIH policy complements The Final Rule and applies to all clinical trials funded by NIH, regardless of whether they are subject to the regulation. Both the NIH policy and the Final Rule will take effect Jan. 18, 2017. Here are some resources to help you better understand the changes:

2. A new NIH policy requires all applications involving clinical trials be submitted through a Funding Opportunity Announcement specifically designed for clinical trials. NIH will no longer accept applications through parent FOAs or other announcements not specific to clinical trials. The aim is to ensure that key trial protocol information will be included in a standard way across clinical trial applications. The target effective date for this policy is Sept. 27, 2017.

3. A policy issued in June, 2016 requires use of a single institutional review board for multi-site studies in order to streamline and expedite IRB review. The first applications that will incorporate the new requirements will be for those with due dates of May 25, 2017. Resources are still under development – stay tuned for more information and guidance.

4. A policy that goes into effect Jan. 1, 2017 requires all NIH-funded investigators and clinical trial staff who are responsible for the conduct, management and oversight of NIH-funded clinical trials to be trained in Good Clinical Practice. GCP  training includes the Principles of the International Conference on Harmonisation and can be achieved through a class, academic training program, or certification from a recognized clinical research professional organization. The good news for OHSU investigators is that OHSU’s Responsible Conduct of Research training through the CITI program qualifies under this new policy.

5. A clinical trial protocol template is being developed with input from the research community. An updated template should be released this fall to be used as a way to organize and standardize key details that should be included in clinical trial protocols.


Inaugural Art of Neuroscience competition accepting submissions

The inaugural “Art of Neuroscience” competition is now accepting entries. All OHSU staff, faculty, and students/trainees are invited to submit an original image that explores the aesthetics of brain and mind as a broad topic.

Voting will be open to OHSU staff, faculty, and students/trainees from November 7 through November 16. A special category and prize are designated for high school students. Prizes for First Place, Honorable Mention, and First Place in the high school category will be awarded at the OHSU Brain Institute Annual Forum on Friday, November 18.

Submission requirements:

  • Format: JPEG
  • Include the title of image, description of image (<100 words), artist’s name, and department or school
  • Deadline: Monday, October 31

Submit images to

Reminder: Applications for University Shared Resources pilot funding due Friday, Oct. 7

This is the final week to submit your applications for the OHSU University Shared Resources Core Pilot Awards program. These awards support OHSU faculty and USR cores by providing pilot funding for principal investigators, especially to support generation of data for new grant applications, as well as to support core development.

Applications must be filled out online through OHSU’s Competitive Application Portal (CAP). Full RFA is provided on CAP and can also be found here.

Please note: Applicants must consult with the director of the designated core prior to application submission. An email from the core director(s) acknowledging a consultation must be received by USR Program Director Andy Chitty before applications can be moved forward for review. Applications are due Oct. 7, 2016, and awards will be announced in late fall.


Groundbreaking study opens door for treating congenital disease before birth

Congenital diseases account for nearly a quarter of perinatal deaths and are important causes of childhood illness and long-term disability. Prenatal screening techniques now make early diagnosis possible, presenting the opportunity to intervene in disease processes before birth. The rapid proliferation of stem cells in the fetus and its immature immune system make in utero gene therapy an attractive target for gene therapy, but ethical considerations and the consequences of disrupting fetal development have so far prohibited human trials.

A breakthrough study by a team of researchers at OHSU and collaborators suggests it may be possible to deliver prenatal gene therapy safely and efficiently in the womb, using the amniotic cavity as a drug reservoir. The study, published in the journal Nucleic Acids Research on Sept. 28, opens the door to potential therapeutic treatments.

The team used a mouse model to determine whether antisense oligonucleotides (ASO), synthetic molecules engineered to target and alter RNA sequences, could be delivered to the amniotic cavity to target gene expression in utero.

A well-characterized ASO was injected into the amniotic fluid and successfully altered expression of a targeted RNA transcript in the liver, kidney, and inner ear of postnatal mice for up to four weeks after birth. The treatment was well tolerated, with 94% of injected mice surviving. The team successfully demonstrated the general ability of ASOs to deliver gene therapy by testing a second ASO.

Further investigation is needed to better understand ASO transport in order to maximize fetal uptake and broaden distribution, but this work establishes that the amniotic cavity has the necessary characteristics to serve as an efficient reservoir for sustained ASO delivery to the developing fetus.

Authors included Lingyan Wang, Ph.D., Han Jiang, Ph.D., and John Brigande, Ph.D., of OHSU’s Oregon Hearing Research Center; Frederic F. Depreux, Ph.D., Francine M. Jodelka, Ph.D. and Michelle L. Hastings, Ph.D., with the Department of Cell Biology and Anatomy, Chicago Medical School, Rosalind Franklin University of Medicine and Science in Chicago; Frank Rigo, Ph.D., of Ionis Pharmaceuticals in Carlsbad, California; and Robert F. Rosencrans, Ph.D., and Jennifer J. Lentz, Ph.D., with the Neuroscience Center and Department of Otorhinolaryngology, LSU Health Sciences Center in New Orleans.

This research was funded by the National Institutes of Health [R01-DC012596 to M.L.H., R21-DC012916 to J.V.B., R01-DC014160 to J.V.B., P30-DC005983 to J.V.B., 1 U54 GM104940 to J.J.L., P30-GM103340 to J.J.L.]; and Foundation Fighting Blindness (to J.J.L., M.L.H.)

Welcome to the Research News Blog

Welcome to the Research News Blog

OHSU Research News is your portal to information about all things research at Oregon Health & Science University. Visit often for updates on events, discoveries, and important funding information.

Participation Guidelines

Remember: information you share here is public; it isn't medical advice. Need advice or treatment? Contact your healthcare provider directly. Read our Terms of Use and this disclaimer for details.